Olema Pharmaceuticals financials
$8.54−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$67.2M | -$58.0M | -$50.1M | -$45.9M | -$47.9M | -$34.9M | -$36.8M | -$37.6M | -$33.5M | -$34.3M | -$30.4M | -$23.3M |
| Net income | -$63.2M | -$53.1M | -$46.1M | -$42.2M | -$43.8M | -$30.4M | -$33.6M | -$34.6M | -$30.4M | -$31.0M | -$26.8M | -$21.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.61 | $-0.52 | $-0.50 | $-0.49 | $-0.51 | $-0.36 | $-0.51 | $-0.60 | $-0.54 | $-0.56 | $-0.49 | $-0.48 |
| EBITDA | -$67.1M | -$57.9M | -$49.9M | -$45.8M | -$47.7M | -$34.7M | -$36.7M | -$37.5M | -$33.4M | -$34.3M | -$30.3M | -$23.3M |
| Operating cash flow | -$45.9M | -$46.0M | -$38.3M | -$34.5M | -$29.9M | -$44.0M | -$26.3M | -$27.0M | -$27.6M | -$23.5M | -$18.5M | -$22.7M |
| Free cash flow | -$46.1M | -$46.0M | -$38.3M | -$34.5M | -$29.9M | -$44.0M | -$26.3M | -$27.0M | -$27.6M | -$23.6M | -$18.5M | -$22.7M |
| Diluted shares | 104.5M | 102.8M | 91.4M | 85.7M | 85.5M | 85.4M | 65.9M | 57.3M | 56.3M | 55.6M | 54.9M | 45.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.6M | $52.5M | $48.3M | $35.3M | $52.5M | $50.6M |
| Short-term investments | $412.5M | $452.8M | $457.1M | $293.7M | $309.4M | $342.1M |
| Total debt | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $0.00 |
| Total assets | $486.6M | $530.6M | $533.4M | $352.5M | $382.0M | $409.6M |
| Total liabilities | $56.0M | $50.2M | $54.9M | $45.0M | $36.8M | $26.2M |
| Shareholders' equity | $430.6M | $480.5M | $478.6M | $307.5M | $345.2M | $383.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology